Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

Jim Cramer, the host of Mad Money, recently took a deep dive into the challenges facing the consumer packaged goods sector, ...

Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Hershey's current stock decline is due to high cocoa prices, but historical trends suggest recovery once prices normalize.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...